Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Ocugen, Inc.

Market Cap 423M 369M 340M 320M 598M 39.91B 603M 4.05B 1.57B 19.64B 1.59B 1.55B 68.26B P/E 2026 *
-5.54x
P/E 2027 * -5.17x
Enterprise Value 361M 315M 290M 273M 510M 34.02B 514M 3.45B 1.34B 16.74B 1.35B 1.32B 58.18B EV / Sales 2026 *
88.4x
EV / Sales 2027 * 38.4x
Free-Float
98.28%
Yield 2026 *
-
Yield 2027 * -
1 day+0.81%
1 week+4.20%
Current month-10.14%
1 month-10.79%
3 months-49.39%
6 months-12.06%
Current year-8.15%
1 week 1.16
Extreme 1.16
1.32
1 month 1.16
Extreme 1.16
1.43
Current year 1.16
Extreme 1.16
2.72
1 year 0.9
Extreme 0.9029
2.72
3 years 0.34
Extreme 0.345
2.72
5 years 0.34
Extreme 0.345
17.65
10 years 0.17
Extreme 0.17
18.77
Manager TitleAgeSince
Chief Executive Officer 62 2019-09-26
Director of Finance/CFO - 2026-02-08
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 62 2019-09-26
Director/Board Member 59 2013-08-31
Director/Board Member 59 2019-08-31
Date Insider Type Main position Quantity % Market Cap.
06-10Free

Director

170,100 0.0502%
06-10Free

Director

170,100 0.0502%
06-10Free

Founder

170,100 0.0502%
Change 5-day change 1-year change 3-year change Capi.($)
+0.81%+4.20%+13.76%+141.43% 416M
-0.34%-1.48%-12.18%-13.39% 43.44B
+3.31%+13.04%+316.43%+562.02% 33.54B
-1.70%-7.90%+8.87%-22.34% 28.48B
+2.84%+2.48%+6.32%+34.93% 29.2B
-0.57%+3.77%+12.66%+20.42% 25.34B
-0.14%+10.03% - - 14.36B
+0.68%-1.19%+54.47%+107.47% 13.05B
+0.54%-3.88%+3.69%+2.24% 12.67B
-0.26%+1.09%+105.03%+80.69% 12.28B
Average +0.22%+1.06%+56.56%+101.50% 21.28B
Weighted average by Cap. +0.13%+0.80%+64.99%+109.12%

Financials

2026 *2027 *
Net sales 4.08M 3.56M 3.28M 3.09M 5.76M 385M 5.81M 38.99M 15.14M 189M 15.3M 14.98M 658M 11.02M 9.62M 8.86M 8.35M 15.58M 1.04B 15.71M 105M 40.91M 511M 41.36M 40.47M 1.78B
Net income -76.84M -67.05M -61.81M -58.2M -109M -7.25B -110M -735M -285M -3.57B -288M -282M -12.4B -85.3M -74.43M -68.61M -64.6M -121M -8.05B -122M -816M -317M -3.96B -320M -313M -13.76B
Net Debt -62.5M -54.54M -50.28M -47.33M -88.34M -5.9B -89.11M -598M -232M -2.9B -235M -230M -10.08B -
Logo Ocugen, Inc.
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. Its technology pipeline includes Novel Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform. It is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal diseases, including retinitis pigmentosa, Stargardt disease and multifactorial diseases, such as dry age-related macular degeneration (dAMD) and geographic atrophy. It is developing a next-generation, inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine, and OCU520, a combination quadrivalent seasonal flu.
Employees
116
Date Price Change Volume
26-06-18 1.250 $ +1.63% 26,222,495
26-06-17 1.230 $ +4.24% 6,326,911
26-06-16 1.180 $ -3.28% 7,714,206
26-06-15 1.220 $ +0.83% 6,340,386
26-06-12 1.210 $ -0.82% 3,743,289
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
1.250USD
Average target price
11.43USD
Spread / Average Target
+814.29%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OCGN Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!